Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21

Despite recent therapeutic improvements, the clinical course of diffuse large B‐cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi‐centre study to evaluate the impact of genomic aberrations detected using a high‐density genome wide‐single nucleotide polymorphism‐based array on clinical outcome in a population of DLBCL patients treated with R‐CHOP‐21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R‐CHOP‐21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p‐ and 15q‐. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R‐CHOP, have been identified by arrayCGH.

[1]  Ewout W. Steyerberg,et al.  Focus on : Contemporary Methods in Biostatistics ( I ) Regression Modeling Strategies , 2017 .

[2]  G. Pruneri,et al.  Non‐negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms , 2010, British journal of haematology.

[3]  W. Chan,et al.  Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma , 2010, British journal of haematology.

[4]  Francesco Bertoni,et al.  Genome wide DNA‐profiling of HIV‐related B‐cell lymphomas , 2010, British journal of haematology.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[7]  Kevin P. Murphy,et al.  Model-based clustering of array CGH data , 2009, Bioinform..

[8]  A. Berk,et al.  Viral manipulation of the host epigenome for oncogenic transformation , 2009, Nature Reviews Genetics.

[9]  Marcus Hutter,et al.  Bayesian DNA copy number analysis , 2009, BMC Bioinformatics.

[10]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[11]  L. Pasqualucci,et al.  Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma , 2008 .

[12]  Francesco Bertoni,et al.  Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion , 2008, British journal of haematology.

[13]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[14]  J. Renauld,et al.  JAK kinases overexpression promotes in vitro cell transformation , 2008, Oncogene.

[15]  T. Golub,et al.  Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas , 2008, Oncogene.

[16]  L. Staudt,et al.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. , 2007, Blood.

[17]  P. Marche,et al.  Analysis of the TCR α-chain rearrangement profile in human T lymphocytes , 2007 .

[18]  J. Armitage.  How I treat patients with diffuse large B-cell lymphoma. , 2007, Blood.

[19]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[21]  Wing Hung Wong,et al.  Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays , 2006, PLoS Comput. Biol..

[22]  Markus Schilhabel,et al.  Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. , 2005, Blood.

[23]  Daniel J. Blankenberg,et al.  Galaxy: a platform for interactive large-scale genome analysis. , 2005, Genome research.

[24]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[25]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[27]  C. Larsson,et al.  Mantle cell lymphomas with clonal immunoglobulin VH3–21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin VH genes , 2005, Modern Pathology.

[28]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[29]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[30]  S. Horvath,et al.  Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma , 2004, Clinical Cancer Research.

[31]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[32]  R. Siebert,et al.  Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. , 2001, Blood.

[33]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[34]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[35]  L. Staudt,et al.  Mechanisms of Disease , 2010 .

[36]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[37]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[38]  P. Marche,et al.  Analysis of the TCR alpha-chain rearrangement profile in human T lymphocytes. , 2007, Molecular immunology.

[39]  L. Staudt,et al.  Characterization of 8 p 21 . 3 chromosomal deletions in B-cell lymphoma : TRAIL-R 1 and TRAIL-R 2 as candidate dosage-dependent tumor suppressor genes , 2005 .

[40]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[41]  H. Sebastian Seung,et al.  Algorithms for Non-negative Matrix Factorization , 2000, NIPS.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.